Programme at a glance

The latest developments in the field of transplantation

ADVANCED PROGRAM NOW AVAILABLE! CLICK HERE TO DOWNLOAD

______________________________________________________________________________________________________

Sunday 24 September
______________________________________________________________________________________________________

 

MORNING:             SPECIALTY UPDATE SYMPOSIA

                               

11.20-14.30             SPECIAL SESSION: THE COOLEST CLINICAL TRIALS IN TRANSPLANTATION SPONSORED BY THE EU
Since the beginning of transplantation, clinical trials entertained in Europe contributed to the advancement of this exciting field. Not only large multicenter studies executed by pharmaceutical companies but also investigator-driven research is strongly present in Europe and contributing to the advancement of our field. Under the umbrella of the FP7 and HORIZON2020 frameworks of the European Commission, the EU is sponsoring large international research networks, also in transplantation. In this session, we listen to the stories of the protagonists in the EU-sponsored projects in the field of solid organ transplantation, and discuss the opportunities and hurdles encountered by these large international collaborative networks.

CHAIRS: Pierre Marquet, Limoges, France
              Maarten Naesens, Leuven, Belgium

11.30                      EU-funding of innovative approaches to solid organ transplantation
                              Jürgen Sautter, European Commission, Brussels - Belgium

11.50                      ONE  - A unified approach to evaluating cellular immunotherapy  in solid organ  transplantation
                               Edward K. Geissler, Regensburg, Germany

12.10                      Bio-DrIM  - Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation
                               Petra Reinke, Berlin, Germany 

12.30-13.10             Lunch break

13.10                      EUROSTAM  - A Europe-wide strategy to enhance transplantation of highly sensitized patients on basis of acceptable HLA mismatches
                               Frans Claas, Leiden, The Netherlands

13.30                      BIOMARGIN  - Biomarkers of renal graft injury
                               Pierre Marquet, Limoges, France

13.50                      COPE - Consortium for organ preservation in Europe: latest news
                               Rutger Ploeg, Oxford, United Kingdom

 

13.00-14.30             Corporate plenary symposia

 

14:45-17:30             OPENING AND PLENARY SESSION 1 | BIG BANG IN TRANSPLANTATION

The session will take you on a journey from the origins of transplantation to the present day. Recent advances in science open the gate to extending human life, defying nature. However, we are also learning from nature as to how to extend the life of organs and the entire human body. On the brink of the biggest adventure of the human race, stepping on a different planet, we face questions about the very essence of humanity.

CREATED BY: Maarten Naesens, Leuven, Belgium
                       Gabriel Oniscu, Edinburgh, United Kingdom

CHAIRS: Josep Maria Grinyó, Barcelona, Spain
              Vassilios Papalois, London, United Kingdom

14.45                      Welcome address by the Congress Chairs
                               Valentín Cuervas-Mons, Madrid, Spain and Antonio Román, Barcelona, Spain

15.00                      ESOT presents: A story never before told!   

15.15                      A patient experience and viewpoint
                               Carole Lamarque, Antwerp, Belgium

15.40                      Hibernation and preservation
                               Robert H. Henning, Groningen, The Netherlands

16.00                      Near future: a glimpse into the ongoing / near future of transplantation
                               Gerald Brandacher, Baltimore, United States

16.25                      KEYNOTE: The human fate from a universal perspective - the race to Mars
                               John Bradford, Atlanta, United States

 

16.45-18.15             Corporate parallel symposia                             

17:45-18:45              TRANSPLANT INTERNATIONAL BEHIND THE SCENES: TEN WAYS TO GET YOUR PAPARE (NOT) REJECTED

This session will provide insight into how the decision is made whether a submitted paper gets accepted or rejected. To inform about parts of the decision process that are usually not visible to the author. To show examples of pitfalls to avoid when submitting a paper. To provide suggestions how to optimize your chances of acceptance.

CHAIRS: Rainer Oberbauer, Vienna, Austria

              Thomas Wekerle, Vienna, Austria;

17:45                         Introduction

                                 Rainer Oberbauer, Vienna, Austria and Thomas Wekerle, Vienna, Austria

17:55                         The editor’s perspective: do's

                                 Rainer Oberbauer, Vienna, Austria

18:15                         The editor’s perspective: dont’s

                                 Thomas Wekerle, Vienna, Austria

18:35                         Interactive discussion with the audience

 

18.30-19.30             Brief oral sessions

                               e-Poster opening

 

______________________________________________________________________________________________________

Monday 25 September
______________________________________________________________________________________________________

 

07.30-09.00          EDUCATIONAL TRACK SESSION 1 | HISTOCOMPATIBILITY: YOUR WORST NIGHTMARE?

CHAIRS: Frans Claas, Leiden, The Netherlands
              David Taube, London, United Kingdom

07:30                     Learning objectives Assessment

07.45                      Application of Luminex® assays before and after transplantation
                               Christophe Legendre, Paris, France

08.00                      From actual towards virtual crossmatch
                               Craig Taylor, Cambridge, United Kingdom

08.15                      HLA epitope matching
                               Sebastiaan Heidt, Leiden, The Netherlands

08.30                      Hidden sensitization: the memory B cell repertoire
                               Oriol Bestard, Barcelona, Spain

 

07.30-09.00          EDUCATIONAL TRACK SESSION 2 | LIVE DONATION

CHAIRS: Paolo Muiesan, Birmingham, United Kingdom
              Raj Thuraisingham, London, United Kingdom

07.45                      Laparoscopy replacing open surgery in live liver donation
                               Ki Hun Kim, Seoul, South Korea

08.00                      Governance and near miss events in live liver donation
                               Juan Carlos García-Valdecasas, Barcelona, Spain

08.15                      Minor clinical abnormalities in kidney donors
                               Rachel Hilton, London, United Kingdom

08.30                      Teaching minimally-invasive live donor nephrectomy
                               Lloyd Ratner, New York, United States

08.00-09.00             Full oral sessions

                               Brief oral sessions

 

09:10-10:40             STATE OF THE ART 1 | ORGAN PRESERVATION AND ENHANCEMENTS

2017: The limitation of available organs and changing demographics are challenges hindering a more rapid growth in organ transplantation. Clinical efforts and a research focus towards making more organs functioning better and increasing the number of organs available for transplantation are ever more important goals. The race is on: will it be organ reconditioning or creating more organs off the shelf? This session will discuss some of the recent developments that may make organ shortage a thing of the past.

CREATED BY: Gabriel Oniscu, Edinburgh, United Kingdom
                       Jacques Pirenne, Leuven, Belgium

CHAIRS: Constantino Fondevila, Barcelona, Spain
              Jacques Pirenne, Leuven, Belgium

09.10                      Organ reconditioning should start in the donor           
                               Gabriel Oniscu, Edinburgh, United Kingdom

09.30                      Ex-situ organ reconditioning: living up to the promise?
                               Peter Friend, Oxford, United Kingdom

09.50                      Origami based tissue engineering
                               Nathaniel Hwang, Seoul, South Korea

10.10                      Choice cuts: growing organs in alternative environments
                               Pablo Juan Ross, Davis, United States

 

09.10-10.40          STATE OF THE ART 2 | MIX AND MATCH: THE RIGHT ORGAN FOR THE RIGHT RECIPIENT

Selecting the right organ for the right patient is an increasing challenge in transplantation. To maintain good outcomes is an increasing challenge in light of both donors and recipients presenting with more unfavorable characteristics. In this session we will focus on global aspects of donation and transplantation and subsequently zoom in on 3 categories of recipients that we commonly encounter in our transplantation clinics. Sergio Leone would name them: The Immunized, The Old and The Diabetic.

CREATED BY: Valentin Cuervas-Mons, Madrid, Spain
                       Eelco de Koning, Leiden, The Netherlands

CHAIRS: Valentín Cuervas-Mons, Madrid, Spain
              Eelco de Koning, Leiden, The Netherlands

09.10                      World Overview on Transplantation Activities (a report of the Global Observatory on Donation & Transplantation)
                               Beatriz Mahillo, Madrid, Spain

09.30                      The immunized patient      
                               Frans Claas, Leiden, The Netherlands

09.50                      The old patient
                               Uwe Heeman, Munich, Germany

10.10                      The diabetic patient
                               Raja Kandaswamy, Minneapolis, United States

 

09:10-10:40             STATE OF THE ART 3 | THE BIOMARKER PERSPECTIVE: PRIME TIME OR PERPETUAL PROMISE?

Personalised treatment seems the new Holy Grail in medicine. But is it achievable and how far have we advanced in transplantation at this point? In this session, we discuss the experience of large consortia in their search for biomarkers for non-invasive diagnosis of rejection, for guidance on immunosuppression and for patient risk stratification. In addition, we will show that the efforts to discover and validate innovative biomarkers are huge and that the pipeline towards clinical implementation is long. Finally, we look into the mirror but also the crystal ball, evaluating the achievements made to date and the promises for the future.

CREATED BY: Oriol Bestard, Barcelona, Spain
                       Maarten Naesens, Leuven, Belgium

CHAIRS: Oriol Bestard, Barcelona, Spain
              Alberto Sanchez-Fueyo, London, United Kingdom

09.10                      BIOMARGIN - systems biology for non-invasive diagnosis of rejection
                               Wilfried Gwinner, Hannover, Germany

09.30                      BIO-DRIM - marker-assisted immunosuppression individualization
                               Petra Reinke, Berlin, Germany 

09.50                      CTOT - biomarkers for transplant risk stratification
                               Peter Heeger, New York, United States

10.10                      The biomarker verdict: prime time or perpetual promise?
                               Dany Anglicheau,  Paris, France

 

11.10-12.40             BIG BANG 1 | TECHNOLOGY ENHANCED  MEDICINE

We are living in a fast forward moving age, where the convergence of rapidly developing technologies are holding the potential to radically improve and disrupt our day to day life. In this session we invite you to have a glance into the future to see how the transplantation will look like years ahead. You will learn a CRISPR way to engineer the human genome, realize that soft robots can support or replace organ function and be impressed by the enormous potential of stem cell biology for generation of human tissues and organs.

CREATED BY: Pietro Cippà, Zurich, Switzerland
                       Olivier Thaunat, Lyon, France

CHAIRS:Pietro Cippà, Zurich, Switzerland
              Olivier Thaunat, Lyon, France

11.10                      A CRISPR way to engineer the human genome
                               Angelo Lombardo, Milan, Italy

11.40                      Cardiovascular devices with a difference - light reflecting balloons and soft robots
                               Ellen Roche, Cambridge, United States

12.00                      KEYNOTE: Genetic, Epigenetic and Cellular approaches to combat disease and aging
                               Juan Carlos Izpisua Belmonte, La Jolla, United States

 

13.00-14.00          FUTURE LEADERS ON STAGE: LIFE-CHANGING STORIES

The Young Professionals in Transplantation have launched a competition to future leaders in transplantation to give a seminal presentation at the ESOT congress. Young Professionals have been selected through a call for action on Social Media. Have a look at the exciting and inspirational presenters that have been selected under 40 years old.

CREATED BY: Francesca Tinti, Rome, Italy
                       Mohammed Zeeshan Akhtar, Oxford, United Kingdom

CHAIRS: Francesca Tinti, Rome, Italy
              Mohammed Zeeshan Akhtar, Oxford, United Kingdom

13.00                      A very personal story of success and failure:
                               My journey to social media
                               Omar Taco, Barcelona, Spain

13.20                      Life-changing event:
                               “To improve is to change, to be perfect is to change often.” (Winston Churchill)
                               Natalie Vallant, Innsbruck, Austria

13.40                      Life-changing event:
                               A Love Worth Giving
                               Luke Yates, London, United Kingdom

 

11.10-12.40             Best abstract challenge

                                Full oral sessions

 

13.00-14.00             Corporate parallel lunch symposia

                                Brief oral sessions

                                Elevator Pitch sessions

 

14:05-15:35             PLENARY SESSION 2 | TRIALS AND TRIBULATIONS IN TRANSPLANTATION

Some of the established frameworks and conventional approaches in transplantation are outdated and hinder further progress in the field: endpoints such as BPAR may be less relevant in the modern era while surrogate endpoints e.g. for long term KTx survival are lacking. We herein attempt to shake up your minds and engage in a mind-set that challenges some of the things considered to be ‘true’ or important. Let us rethink the relevance and value of established tools for promotion of progress in clinical science and face the need for change and the challenges that come with it. Welcome to a session that will be rebellious and provocative but also constructive and productive.

CREATED BY: Mark Dahlke, Regensburg, Germany
                       Alexandre Loupy, Paris, France

CHAIRS: Robert Montgomery, New York, United States
              Gabriel Oniscu, Edinburgh, United Kingdom

14.05                      What to do when randomized controlled trials stop working
                               Alexandre Loupy, Paris, France

14.25                      I can induce tolerance but nobody wants to believe me
                               Alberto Sánchez, London, United Kingdom

14.45                      Define Success in the 2017 transplant world; a path to happiness
                               Flavio Vincenti, San Francisco, United States

15.05                      Managing change with big data

 

16:00 -17:00            BIG BANG 2 | VALUE AND COSTS OF SCIENCE AND PATIENT CARE IN TRANSPLANTATION: THE UNWANTED TRUTH

The idea of this session is to critically reflect on the value and cost-relationship in transplantation – in reference to science, progress, quality of life, patient behaviour including compliance but also regulatory obligations such as working week regulations. The value of life and costs of suffering as well as the implications of money and patient but also physician behaviour are much debated issues in modern health care. We will touch on strategic thinking in research funding, the implementation from lab inventions to successful enterprises and what can be learned from the free market. In this session, we aim to draw a modern picture of the actual circumstances in healthcare with respect to both the finances of a treatment, but also patient behaviour and their implications on outcome and quality of care. You will experience a different and fresh view on patient care in a rapidly changing environment.

CREATED BY: Stefan Schneeberger, Innsbruck, Austria
                       Dorry Segev, Baltimore, United States

CHAIRS: Stefan Schneeberger, Innsbruck, Austria
              Dorry Segev, Baltimore, United States

16.00                      The price for progress
                               Wim Bens, Maastricht, The Netherlands

16.20                      The changing circumstances in health care and their consequences
                               Scott Halpern, Philadelphia, United States

16.40                      The price for patient satisfaction
                               Sheila Jowsey, Rochester, United States

 

16.00-17.00             Brief oral sessions

                              

16.00-18.00             Full oral sessions

                                               

16.00-18.00           FROM LEARNERS TO LEADERS AND CAMPFIRE SESSION

CHAIR: Wojciech Polak, Rotterdam, The Netherlands

16:00                      ESOT Education - ESOT Transplant Live & Live Events
                               John Forsythe, Edinburgh, United Kingdom
                               Frank Dor, London, United Kingdom

16:10                      KEYNOTE:  Time is now – modern education
                               William Plant, Cork, Ireland

16:40                      From learners to leaders: introducing the Freudian Walk                          

                               O Captain, My Captain – how the journey continues
                               Luca Toti, Rome, Italy

16:50                      A growing experience – part 1: keeping the balance
                               Maruska Nizzi, Milan, Italy

17:00                      Freudian Walk (3 crews/3 topics about learning/communicating/sharing)

Crew 1 with captain Wojciech Polak, Rotterdam, The Netherlands
Crew 2 with captain Jacopo Romagnoli, Rome, Italy
Crew 3 with captain Luca Toti, Rome, Italy

The Campfire

17:20                      A growing experience - part 2: tips & tricks from senior experts

                               Maruska Nizzi, Milan, Italy

17:30                      Campfire Live (3 crews/3 campfires)

Crew 1 mentored by captain Wojciech Polak, Rotterdam, The Netherlands
Crew 2 mentored by captain Jacopo Romagnoli, Rome, Italy
Crew 3 mentored by captain Luca Toti, Rome, Italy

17:50                      Sharing is Caring – a “post” to the Leaders
                               Maruska Nizzi, Milan, Italy
                               Luca Toti, Rome, Italy

 

17.00-18.00          THE DEVIL’S ADVOCATE: A MODERATED CONTROVERSY IN BASIC SCIENCE

The format of this session will be the presentation of the article by the author followed by a critical discussion by the “opponent” and a rebuttal and general discussion with the audience. It will be a highly interactive session.

CREATED BY: Olivier Thaunat, Lyon, France
                       Thomas Wekerle, Vienna, Austria

New insights in the priming of recipient's immune system
Donor dendritic cell-derived exosomes promote allograft-targeting immune response.
Liu Q, Rojas-Canales DM, Divito SJ, Shufesky WJ, Stolz DB, Erdos G, Sullivan ML, Gibson GA, Watkins SC, Larregina AT, Morelli AE. J Clin Invest. 2016 Aug 1;126(8):2805-20. doi: 10.1172/JCI84577. Epub 2016 Jun 27

17:00                     Defender: Adrian Morelli, Pittsburgh, United States

17:20                     Opponent:  Gavin Pettigrew, Cambridge, United Kingdom

17:30                     Discussion

Impact of microbiota on transplantation outcomes
The composition of the microbiota modulates allograft rejection
Yuk Man Lei, Luqiu Chen, Ying Wang, Andrew T. Stefka, Luciana L. Molinero, Betty Theriault, Keston Aquino-Michaels, Ayelet S. Sivan, Cathryn R. Nagler, Thomas F. Gajewski, Anita S. Chong, Caroline Bartman and Maria-Luisa Alegre. Journal of Clinical Investigation, June 20, 2016

17:40                     Defender: Maria Luisa Alegre, Chicago, United States

17:50                     Opponent 

18:00                     Discussion

 

17.00-18.00             Brief oral sessions

 

18.00-19.30             Corporate Plenary Symposium

 

______________________________________________________________________________________________________

Tuesday 26 September
______________________________________________________________________________________________________

 

07.30-09.00             EDUCATIONAL TRACK SESSION 3 : ABOVE AND BELOW THE DIAPHRAGM

CHAIRS: Jim Egan, Dublin, Ireland
              Annemarie Weissenbacher, Oxford, United Kingdom

07.45                      Old and new listing criteria for lung and heart transplantation
                               John Dark, Newcastle, United Kingdom

08.00                      Old and new listing criteria for liver, pancreas and intestinal transplantation
                               Peter Friend, Oxford, United Kingdom

08.15                      How do factors from above the diaphragm impact on the outcome of transplantation of organs below the diaphragm?
                               Stephan Eschertzhuber, Innsbruck, Austria

08.30                      Combined transplanted patients - Which organ drives the immunosuppressive regimen? 
                               Nassim Kamar, Toulouse, France

 

07.30-09.00             EDUCATIONAL TRACK SESSION 4 : PATHOPHYSIOLOGY AND ENDPOINTS ON TOLERANCE 

CHAIRS: Cristina Cuturi, Nantes, France
              Nina Pilat, Vienna, Austria

07.45                      Clinical tolerance studies
                               Megan Sykes, New York, United States

08.00                      Endpoints and biomarkers for clinical tolerance
                               Birgit Sawitzki, Berlin, Germany

08.15                      Macrophages and the induction of tolerance
                               Jordi Orchando, New York, United States

08.30                      T-reg induced allograft tolerance in human
                               Giovanna Lombardi, London, United Kingdom

 

08.00-09.00             Full oral sessions

                                Brief oral sessions

 

09:10 - 10:40           STATE OF THE ART 4 | NEW CONCEPTS IN TRANSPLANT INFECTIOUS DISEASES: MICROBIOTA, AND BEYOND

New tools have allowed an unprecedented genetic insight into the composition of our microbiota and our virome. First, we explore the role of the virome and microbiota as it relates to transplantation including potential clinical applications. We aim to elaborate on the impact in transplantation on an individual and epidemiological level. The immunomodulatory role of viruses in transplantation are often mentioned – but does this concept hold up? A critical appraisal of the concept of the indirect effects of viruses is presented. The new anti-HCV drugs have made eradication of HCV in virtually all patients a realistic goal, but how important is a complete control of viral replication in the context of HCV and other viruses?

CREATED BY: Marina Berenguer, Valencia, Spain
                       Nicolas Müller, Zurich, Switzerland

CHAIRS: Maria Luisa Alegre, Chicago, United States
              Marina Berenguer, Valencia, Spain

09.10                      Transkingdom interplay - the complex interactive world of the microbiome
                               Wang Dave, St. Louis, United States

09.30                      Knowledge and clinical applications of microbiota in transplantation
                               Frederick Bushman, Philadelphia, United States

09.50                      Viruses and the recipient immune response: relevant crosstalk in transplantation
                               Oriol Manuel, Lausanne, Switzerland

10.10                      The impact of HCV treatment on liver transplantation
                               Michael R. Charlton, Salt Lake City, United States

 

09:10 - 10:40           STATE OF THE ART 5 | CELL THERAPY IN CLINICAL TRIALS

Cell therapy may be a suitable adjunct to conventional immunosuppression. Despite a major enthusiasm, however, major issues emerged in the first clinical applications. The question now is: how can technical and regulatory hurdles be overcome within a reasonable time frame? Will cell therapy ever be commercially interesting and will its implementation enhance solid organ transplantation? Experts share their experience and explain what we might expect from cell therapy tomorrow and in 10 years.

CREATED BY: Pietro Cippà, Zurich, Switzerland
                       Marc Dahlke, Regensburg, Germany

CHAIRS: Marc Dahlke, Regensburg, Germany
              Thomas Wekerle, Vienna, Austria

09.10                      Technical and regulatory issues. From the idea to the clinical application
                               Marlies Reinders, Leiden, The Netherlands

09.30                      Sharing clinical experience. What can we learn from hematologists?
                               Francesco Dazzi, London, United Kingdom

09.50                      Translational studies. Why do we need cell therapy if we cannot avoid severe immunosuppression?
                               Suzanne T. Ilstad, Louisville, United States

10.10                      The future: Clinical applications of stem cells in the context of transplantation vs. regeneration?    
                               Martin Johannes Hoogduijn, Rotterdam, The Netherlands

 

09:10 - 10:40           STATE OF THE ART 6 | ONE FOR ALL OR ALL FOR ONE; MOVING AWAY FROM PROTOCOLIZED MEDICINE

The ultimate goal of transplantation is long-term survival with a well-functioning graft. Operationalization of post-transplant care with protocols based on evidence from clinical trials has had an important impact on the overall outcome in transplantation. It is increasingly recognized though, that the ‘one size fits all’ approach does not always optimally reflect the patient’s individual need. Hence, the concept of personalized medicine is on everyone’s lips. This session aims to confront the reality by focusing on four important topics in the field.

CREATED BY: Georg Böhmig, Vienna, Austria
                       Nicolas Müller, Zurich, Switzerland

CHAIRS: Georg Böhmig, Vienna, Austria
              Nicolas Müller, Zurich, Switzerland

09.10                      Is transplantation ready for systems medicine?            
                               Rainer Oberbauer, Vienna, Austria

09.30                      Individualized antimicrobial prophylaxis
                               Jay Alan Fishman, Boston, United States

09.50                      Phenotypic diversity of rejection and allograft dysfunction
                               Phil Halloran, Edmonton, Canada

10.10                      Tailored immunosuppression
                               Christian Hugo, Dresden, Germany

 

11.10-12.40          ASIA LEADING THE WAY (Joint Session with the Asian Society for Transplantation)

This session was jointly organized with the Asian Society for Transplantation and aims to highlight some of the significant advancements in transplantation achieved in the recent past. We are proud to bring to your attention, programs and topics with significant thrive from our partners in Asia.  

CHAIRS: Jan Lerut, Brussels, Belgium
              Dennis Serrano, Quezon City, Philippines

11.20                      Tissue Repair and its Relevance to Transplantation
                               Nathaniel S. Hwang, Seoul, Korea

11.40                      Challenges in Increasing Organ Donation in Asia
                               Romina Danguilan, Manila, Philippines

12.00                      ABO Incompatible Kidney Transplantation: Future Directions
                               Shiro Takahara, Osaka, Japan

12.20                      State of the Art of Living Donor Liver Transplantation 
                               Chao Long Chen, Kaohsiung City, Taiwan

 

11.10-12.40             BIG BANG 3 | INNOVATION IN IMMUNOMEDICATION: THE MODERN PROMETHEUS

Putting their feet in those of Dr Frankenstein, scientists have started stitching disparate biological pieces to create new therapeutic opportunities. far from sci-fi fantasies, these therapeutic innovations have already shown promising results in the field of cancer therapy. Their potential to revolutionize solid organ transplantation will be scrutinized during this Big Bang session.

CREATED BY: Josep Maria Grinyó, Barcelona, Spain
                       Olivier Thaunat, Lyon, France

CHAIRS: Julien Zuber, Paris, France

11.10                      Deciphering and targeting protein-protein interactions: a new challenge in biomedicine
                               Juan Fernández Recio, Barcelona, Spain

11.30                      The potential of bispecific antibodies

11.50                      Alloantigen-specific regulatory T-cells generated with a chimeric antigen receptor
                               Megan Levings, Vancouver, Canada

12.10                      Systems biology applications for prognostication and therapeutics
                               Patrick Aloy, Barcelona, Spain

 

11.10-12.40              Full oral sessions

                               Elevator Pitch sessions

 

13.00-14.00             Corporate Parallel lunch Symposia

                               Brief oral sessions

 

13.00-14.00          SURROGATE ENDPOINTS INTERNATIONAL WORKSHOP

Drug development in transplantation has diminished due to the lack of fitting endpoints, the long timespan between transplantation and graft failure and the low rates of early rejection. At the same time, we find patients suffering from long-term graft loss. Hence it is paramount to establish new principles to allow development of novel therapeutics to treat and prevent this from happening. One of the main objectives in our thrive to address this is to identify and validate surrogate markers for long-term graft outcome and identify novel endpoints for trials and drug development. The field of transplantation is facing one of the greatest challenges hindering further advancement of this field and all individuals and institutions involved in this field need to work together to prevail.
In this interactive session, we will discuss the need for new endpoints in the field of transplantation, the potential and problems with histology, the applicability of donor-specific antibodies, and the promise of combined calculated markers as surrogate endpoints. We will discuss the progress that has and can be achieved by transplant societies and health authorities. The session will focus on kidney transplantation, although the methodology and conclusions are likely valid also for other organs.

CREATED BY: Maarten Naesens, Leuven, Belgium
                       Stefan Schneeberger, Innsbruck, Austria

CHAIRS: Maarten Naesens, Leuven, Belgium
              Stefan Schneeberger, Innsbruck, Austria

13.00                      Why do we need new endpoints
                               Mark Stegall, Rochester, United States

13.10                      The potential of combined calculated surrogate endpoints
                               Alexandre Loupy, Paris, France

13.22                      The difficult but important place of histology as endpoint
                               Maarten Naesens, Leuven, Belgium

13.34                      DSAs as surrogate endpoint for drug development
                               Peter Nickerson, Winnipeg, Canada TBC

13.46                      Panel discussion

 

14:05-15:35             PLENARY SESSION  3 | INNOVATION UNDER PRESSURE: TRANSPLANT PATIENT CARE IN 2020

Health care is undergoing a fundamental change. While new fields in medicine are emerging and short-term results are satisfactory, long-term care of patients after transplantation is more complex and challenging than ever. While novel technologies may help to effectively monitor patients after transplantation, novel structures and business models are warranted to ensure optimal patient care and advancement of the field.

CREATED BY: Marina Berenguer, Valencia, Spain
                       Antonio Roman, Barcelona, Spain

CHAIRS: John Forsythe, Edinburgh, United Kingdom
              Christophe Legendre, Paris, France

14.05                      Prospects and pushbacks in hand face uterus abdominal wall penile transplant and others
                               Wei-Ping Andrew Lee, Baltimore, United States

14.25                      Beyond survival: quality of life after transplantation
                               Lianne Singer, Toronto, Canada

14.45                      New tech for new patients: digital communication and self-monitoring  
                               Magali Giral, Nantes, France

15.05                      New models for patient care: wish for what you care for
                               Marcel Levi, London, United Kingdom

 

16.00-17.00             BIG BANG 4 | AGEING AND IMMORTALITY

In this session, we discuss the changing demographics of donors and recipients and its impact on transplantation in reference to organ quality, ischemia-reperfusion injury and immunosenescence. In addition, the biology of ageing and the concept of accelerated ageing after transplantation with its implications on the fate of the graft and the patient are being addressed. As a consequence of the changing demographics, transplant allocation organisations are implementing age-matching in their allocation procedures. The benefits and the potential drawbacks of these important changes are discussed. Finally, we will evaluate innovative ways to halt or slow down these ageing processes, and discover the clues to immortality.

CREATED BY: Maarten Naesens, Leuven, Belgium
                       Olivier Thaunat, Lyon, France

CHAIRS: Maarten Naesens, Leuven, Belgium

16.00                      Older graft, older recipients, young ideas
                               Stefan Tullius, Boston , United States

16.20                      Accelerated ageing after transplantation
                               Peter Stenvinkel, Stockholm, Sweden

16.40                      Halting aging: the science of rejuvenation
                               Brian Kennedy, Novato, United States

 

16.00-17.00             Brief oral sessions

 

16.00-17.00          THE DEVIL'S ADVOCATE: CONTRADICTORY DISCUSSION OF CLINICAL SCIENCE

The format of this session will be the presentation of the article by the author followed by a critical discussion by the “opponent” and a rebuttal and general discussion with the audience. It will be a highly interactive session.

CREATED BY: Rainer Oberbauer, Vienna, Austria
                       Josep Maria Grinyó, Barcelona, Spain

CHAIRS: Rainer Oberbauer, Vienna, Austria
              Josep Maria Grinyó, Barcelona, Spain

Ethical debate
Allocating Organs to Cognitively Impaired Patients.
Scott D. Halpern, M.D., Ph.D., and David Goldberg, M.D., M.S.C.E. N Engl J Med 2017; 376:299-301January 26, 2017DOI: 10.1056/NEJMp1613858

16:00                     Defender: Scott Halpern, United States

16:20                     Opponent: Michael Bos, Leiden, The Netherlands

16:30                     Discussion

Expensive but useless?
Clinical value of C1q assay in antibody-mediated rejection
Evaluation of C1q Status and Titer of De Novo Donor-Specific Antibodies as Predictors of Allograft Survival. Wiebe, Gareau, Pochinco, Gibson, Ho, Birk, Blydt-Hansen, Karpinski, Goldberg, Storsley, Rush, Nickerson. Am J Transplant. 2017 Mar;17(3):703-711. doi: 10.1111/ajt.14015. Epub 2016 Oct 3.

16:40                     Defender: Peter Nickerson, Winnipeg, Canada

16:50                     Opponent: Denis Glotz, Paris, France

17:00                     Discussion

 

17.00-18.30            Corporate Plenary/Parallel Symposium

                                Full oral sessions

 

18.30-19.30             ESOT General Assembly

                                Elevator Pitch sessions

                                Brief oral sessions

 

______________________________________________________________________________________________________

Wednesday 27 September
______________________________________________________________________________________________________

 

07.30-09.00             EDUCATIONAL TRACK SESSION 5 : INFECTION DISEASES

CHAIRS: Alain Le Moine, Brussels, Belgium
              Frederike Bemelman, Amsterdam, The Netherlands

07.45                      Prophylaxis of infections in solid organ transplantation (including donor derived infections)
                               Jay Alan Fishman, Boston, United States

08.00                      Infectious diseases in the central nervous system of solid organ transplant patients            
                               Peter Portegies, Amsterdam, The Netherland

08.15                      Fungal and yeast Infections in SOT patients
                               José María Aguado, Madrid, Spain

08.30                      Impact of infection on chronic allograft dysfunction and allograft survival after solid organ transplantation
                               Oriol Manuel, Lausanne, Switzerland

 

07.30-09.00             EDUCATIONAL TRACK SESSION 6 : THE ALLOGRAFT PHENOTYPE AND ITS CLINICAL IMPLICATIONS

CHAIRS: Lorna Marson, Edinburgh, United Kingdom
              Marlies Reinders, Leiden, The Netherlands

07.45                      Allo-immune responses: what a clinician should know
                               Frans Claas, Leiden, The Netherlands

08.00                      Rejection phenotypes across organs: revisiting the basics
                               Chris Bellamy, Edinburgh, United Kingdom

08.15                      How to integrate complex histological phenotypes in routine clinical decision making?
                               Daniel Serón, Barcelona, Spain

08.30                      Time to make computer-assisted instead of eminence-based decisions?
                               Alexandre Loupy, Paris, France

 

08.00-09.00             Full oral sessions

                                Brief oral sessions

 

09:10 - 10:40           STATE OF THE ART 7 | DONOR MANAGEMENT – CAN WE FURTHER EXTEND THE POTENTIAL DONOR POOL?

The prerequisite for successful transplantation is the availability of organs. At the same time, selecting suitable organs for transplantation is critical in order to guarantee optimal short- and long-term outcomes. During the last years, we have experienced an increasing interest in strategies to optimize donor management, especially since liberalization of donor criteria has been introduced within the field. In this session, we want to address the idea of further extending the potential donor pool. The focus will be recent innovative approaches and potential risk factors, that might limit further expansion. In this session we want to engage all professionals involved in this topic, including anaesthesiologists, intensivists, nurses, coordinators and transplant physicians in a lively exchange and discussion.

CREATED BY: Arne Neyrinck, Leuven, Belgium
                       Jacques Pirenne, Leuven, Belgium

CHAIRS: Arne Neyrinck, Leuven, Belgium
              Jacques Pirenne, Leuven, Belgium

09.10                      How controlled is my DCD?
                               Sophie Van Cromphaut, Leuven, Belgium

09.30                      Should I perfuse my donor?
                               Simon Messer, Cambridge, United Kingdom

09.50                      Tribulation in designing donor intervention studies
                               Claus Niemann, San Francisco, United States

10.10                      How clean is my donor?
                               Margaret Hannan, Dublin, Ireland

 

09:10 - 10:40           STATE OF THE ART 8 | PUSHING THE BOUNDARIES IN LIVING DONATION

Live donation has become routine practice in many countries. The expansion of the acceptance criteria for live kidney donors is now challenged by emerging evidence for an increased relative risk for the development of renal failure on the long run. In this context, it is even more important how transplant professionals provide an individual risk assessments for potential donors. But how can we ensure that donors understand the potential risks? Do we have a good screening tool to assess potential psychological risks for live donors? Can we step away from standardized surgical approaches for live donor nephrectomy and adopt a tailor made approach? Should living donor liver transplantation be advocated to replace deceased donor liver Tx? This session focuses on the balance between pushing the limits in the context of potential short and long-term complications in this field.

CREATED BY: Frank Dor, London, United Kingdom
                       Gabriel Oniscu, Edinburgh, United Kingdom

CHAIRS: Barış Akin, Ankara, Turkey
              Lisa Burnapp, Watford, United Kingdom

09.10                      To be or not to be a donor -  How can we make sure potential donors understand the risks?
                               Aisling Courtney, Belfast, Ireland

09.30                      Psychosocial evaluation of live donors - the need for a tool to determine the psychological risk
                               Fabienne Dobbels, Leuven, Belgium

09.50                      Tailor made live donor nephrectomy: a conversation between two surgeons
                               Frank Dor, London, United Kingdom and Gabriel Oniscu, Edinburgh, United Kingdom

10.10                      Should live liver donor transplantation be advocated to substitute deceased donor liver Tx?
                               Yaman Tokat, Istanbul, Turkey

 

09:10 - 10:40           STATE OF THE ART 9 | CELLULAR INTERACTIONS IN REJECTION

Transplant rejection involves a coordinated attack of the graft by the recipient’s innate and the adaptive immune systems. Although direct visualization of this complex cellular interplay as made possible by recent technological progresses has greatly improved our understanding of rejection pathophysiology, it has also led to unexpected observations. Indeed, like in other chronic inflammatory conditions, organized lymphoid tissue develop in allografts. This session will provide an update on cellular interactions in rejection and will discuss whether intragraft tertiary lymphoid organs contribute to graft rejection and/or tolerance.

CREATED BY: Lorna Marson, Edinburgh, United Kingdom
                       Olivier Thaunat, Lyon, France

CHAIRS: Lorna Marson, Edinburgh, United Kingdom
             Carla Baan, Rotterdam, The Netherlans

09.10                      Visualizing cell trafficking and the underlying allosensitization by two-photon microscopy
                               Adrian Morelli (from T Starzl institute)

09.30                      T-cell migration to vascularized transplants
                               Fadi Lakkis, Pittsburgh, United States

09.50                      Lymphoid neogenesis: a tribute to the travelers
                               Nancy Ruddle, New Haven, United States

10.10                      Intragraft tertiary lymphoid organs: friends and foes
                               Olivier Thaunat, Lyon, France

 

11:00 - 13:00           PLENARY SESSION 4 AND CLOSING | LEADERSHIP IN TRANSPLANTATION AND PRESIDENTIAL SESSION

Leadership is a key element in our professional lives, yet the attention to professionalism in this area has not received much attention. Much of the potential in our field could be mobilized by enhancing the understanding of the principles in modern leadership. In this final plenary session, you will hear from individuals within and outside of transplantation about their experience and their own views on leadership.
As per the tradition of the ESOT conference, you will also be presented with a summary of the  most exciting innovations that have been discussed during the congress in this session.

CREATED BY: Lorna Marson, Edinburgh, United Kingdom
                       Stefan Schneeberger, Innsbruck, Austria

CHAIRS: Thierry Berney, Geneva, Switzerland; ESOT CURRENT PRESIDENT
             Stefan Schneeberger, Innsbruck, Austria; ESOT PRESIDENT ELECT

11.00                      Clinical: What's hot!
                               Dennis Hesselink, Rotterdam, The Netherlands

11.20                      Basic Science: What's hot!
                               Oriol Bestard, Barcelona, Spain

11.40                      Leadership in transplantation!
                               Dorry Segev, Baltimore, United States and Robert Montgomery, New York, United States

12.10                      KEYNOTE Leadership
                               Javier Solana, Madrid, Spain

12.30                      Presidential address
                               Stefan Schneeberger, Innsbruck, Austria